Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 20/20 | 0.38 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | NEK4 | P51957 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.38 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.38 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.38 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22437422 | 0.94 | MCL1 (0.39) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL23111365 | 0.92 | MCL1 (0.33) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL19615941 | 0.92 | MCL1 (0.39) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL23091314 | 0.91 | MCL1 (0.44) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL22437379 | 0.88 | MCL1 (0.44) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL23111056 | 0.86 | MCL1 (0.35) | MCL1 | |
| SCHEMBL23111017 | 0.84 | MCL1 (0.36) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL19615394 | 0.84 | MCL1 (0.34) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL22437374 | 0.82 | MCL1 (0.59) | MCL1EEF2KMARK3AXLBCL6 | |
| SCHEMBL23828818 | 0.81 | MCL1 (0.34) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710449-B1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | BROAD INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| EP-3710449-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | The Broad Institute, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710447-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | FOXM1, CCNT2, CCND2 | MCL1 34/4885EEF2K 1419/4885MARK3 2140/4885 |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | FOXM1, CCNT2, CCND2 | MCL1 34/4885EEF2K 1419/4885MARK3 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.